Need for intensive, early glycaemic control in patients with type 2 diabetes

British Journal of Cardiology

Volumn 7, Issue 10, 2000, Pages 625-631

  Campbell, I W ^a  

^a VICTORIA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEGLITINIDE; METFORMIN; NATEGLINIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA; SULFONYLUREA RECEPTOR; TOLBUTAMIDE; TROGLITAZONE;

ANEMIA; BLOOD GLUCOSE MONITORING; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONSERVATIVE TREATMENT; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TOLERANCE; EDEMA; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; LIVER TOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; UPPER RESPIRATORY TRACT INFECTION;

EID: 0033755062     PISSN: 09696113     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Morbidity and mortality in diabetics in the Framingham population: Sixteen-year follow-up study
2. Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus
3. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial
4. Global burden of diabetes, 1995-2025. Prevalence, numerical estimates, and projections
5. A desktop guide to type 2 diabetes mellitus
6. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study
7. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
8. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
9. Measuring clinical performance and outcomes from diabetes information systems: An observational study
10. A 9 year update of a randomised, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus (UKPDS 17)
11. Stepwise and combination drug therapy for the treatment of NIDDM
12. Combination therapy for type 2 diabetes
13. Pharmacologic therapy for type 2 diabetes mellitus
14. The antihyperglycaemic effect of metformin: Therapeutic and cellular mechanisms
15. Worldwide experience of metformin as an effective glucose-lowering agent: A meta-analysis
16. Efficacy of metformin in type II diabetes: Results of a double-blind, placebo-controlled, dose-response trial
17. Metformin: A review of its metabolic effects
18. A new oral therapy for diabetes management: Alpha-glucosidase inhibition with acarbose
19. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycaemic control over 3 years (UKPDS 44)
20. Thiazolidinediones in the treatment of insulin resistance and type II diabetes
21. Rosiglitazone
22. Thiazolidinediones: A new class of antidiabetic drugs
23. Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus
24. Rosiglitazone taken once daily provides effective glycaemic control in patients with type 2 diabetes mellitus
25. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes
26. Stimulation by insulin release by repaglinide and glibenclamide involves both common and distinct processes
27. Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin
28. Effects of the new oral hypoglycaemic agent nateglinide on insulin secretion in type 2 diabetes mellitus
29. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycaemia
30. Intensive conventional insulin therapy for type II diabetes. Metabolic effects during a 6-month outpatient trial
31. Starting insulin therapy in patients with type 2 diabetes: Effectiveness, complications, and resource utilization
32. The UK Prospective Diabetes Study (author's reply)
33. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49)
34. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study
35. Antihyperglycaemic efficacy, response prediction and dose-response relations of treatment with metformin and sulphonylurea, alone and in primary combination
36. Metabolic effects of metformin addition to chronic glibenclamide treatment in type 2 diabetes
37. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus
38. Effect of metformin/glyburide on fasting plasma glucose in type 2 diabetes
39. A comparison of preconstituted, fixed combinations of low-dose glyburide plus metformin versus high-dose glyburide alone in the treatment of type 2 diabetic patients
40. Effect of metformin/glyburide tablets on HbA1c in first-line treatment of type 2 diabetes
41. Different effects of insulin and oral antidiabetic agents on glucose and energy metabolism in type 2 (non-insulin-dependent) diabetes mellitus
42. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients
43. Combination therapy with pioglitazone and sulphonylureas in patients with type 2 diabetes
44. The effect of combination therapy with pioglitazone and sulphonylureas on the lipid profile in patients with type 2 diabetes
45. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus
46. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multi-center controlled clinical trial
47. Effect of an alpha-glucosidase inhibitor combined with sulphonylurea treatment on glucose metabolism in patients with non-insulin-dependent diabetes mellitus
48. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: A randomized controlled trial
49. Combination therapy with pioglitazone and metformin in patients with type 2 diabetes
50. Adding pioglitazone to metformin therapy improves the lipid profile in patients with type 2 diabetes
51. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes
52. Controlling glucose and blood pressure in type 2 diabetes: Starting treatment earlier may reduce complications